Abstract

As of December 2019, there has been an outbreak of severe respiratory syndrome coronavirus-2 (SARS-CoV-2) in China. Around 16% of patients developed acute respiratory distress syndrome, and 1%–2% died. There is no specific treatment reported. A pandemic related to Coronavirus is one of the most significant health crises in human history. In spite of a massive influx of cases, SARS-CoV-2 is still untreatable. Both old and novel virologic medicines were tested in order to develop a novel drug or vaccine. In advanced clinical trials in the US, favipiravir is currently approved for treating influenza infections in Japan, and it has been approved for treating SARS-CoV-2 or COVID-19 infections in Japan. Studies have shown that favipiravir can treat mild to moderate COVID-19 infections. The present review examines the role and use of favipiravir in the treatment of COVID-19. The purpose of this review is to provide evidence obtained from a variety of authentic sources. Current research is evaluating favipiravir for treating Coronavirus infections.

Keywords: COVID-19, SARS-CoV-2, Favipiravir, Antiviral drugs, Nucleocapsids, Fecal-oral, Respiratory failure.
Fulltext HTML PDF ePub
1800
1801
1802
1803
1804